Predicting Risk of Thyroid Cancer With AI

Technology Networks | October 25, 2019

Thyroid nodules are small lumps that form within the thyroid gland and are quite common in the general population, with a prevalence as high as 67%. The great majority of thyroid nodules are not cancerous and cause no symptoms. However, there are currently limited guidelines on what to do with a nodule when the risk of cancer is uncertain. A new study from The Sidney Kimmel Cancer Center - Jefferson Health investigates whether a non-invasive method of ultrasound imaging, combined with a Google-platform machine-learning algorithm, could be used as a rapid and inexpensive first screen for thyroid cancer. "Currently, ultrasounds can tell us if a nodule looks suspicious, and then the decision is made whether to do a needle biopsy or not," says Elizabeth Cottril, MD, an otolaryngologist at Thomas Jefferson University, and clinical leader of the study. "But fine-needle biopsies only act as a peephole, they don't tell us the whole picture. As a result, some biopsies return inconclusive results for whether or not the nodule may be malignant, or cancerous, in other words." If examining the cells of a needle biopsy proves inconclusive, the sample can be further tested via molecular diagnostics to determine risk of malignancy. These tests look for the presence of certain mutations or molecular markers that are associated with malignant thyroid cancers. When nodules test positive for high risk markers or mutations, the thyroid may be surgically removed. However, the standards for when to use molecular testing are still in development, and the test is not yet offered in all practice settings, especially at smaller community hospitals.

Spotlight

The F0-BABY series comprise optimal entry level autoclavable fermenters/bioreactors for microbial and cell culturing bioprocessing activities. Modular design allows the expansion of hardware and software.

Spotlight

The F0-BABY series comprise optimal entry level autoclavable fermenters/bioreactors for microbial and cell culturing bioprocessing activities. Modular design allows the expansion of hardware and software.

Related News

INDUSTRIAL IMPACT

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

ShouTi Inc | February 18, 2022

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecute the most challenging structure-based drug discovery targets, including G-protein coupled receptors (GPCRs), and deliver discovery assets to ShouTi’s development pipeline. In addition, Basecamp Bio will explore selective partnerships to tackle high value targets pursued by the biopharmaceutical industry. Basecamp Bio is led by Yingli Ma, Ph.D., President, who brings close to 15 years of research, technology, and drug discovery experience including her previous role as general manager of Amgen Shanghai Research Center. Dr. Ma led Amgen’s global structural biology and drug discovery programs in cardiometabolic and inflammatory diseases. “By bringing together our deep expertise in structure-based drug design with leading drug discovery technologies, we aim to create orally-available small molecule medicines against some of the most complex targets including those validated by biologics,” said Dr. Ma. “With all of these breakthrough technologies under one roof, and access to the Shanghai biotech contract research organization ecosystem as a resource, Basecamp Bio has the ability to greatly accelerate the discovery of assets with best-in-class potential.” Basecamp Bio’s technology leverages the power of cryo-electron microscopy, machine learning and X-ray crystallography, as the basis for its molecular designs. The company employs state-of-the-art small molecule hit identification, including DNA encoded library technology and affinity mass spectrometry selections for membrane proteins. This is integrated with cutting-edge computational chemistry and medicinal chemistry along with a matrix of pharmacological assay platforms. ShouTi’s exceptional experience with cell surface receptor signaling and pharmacology will further enable Basecamp Bio to achieve its goal of designing medicines with optimal pharmaceutical properties to address patient needs. “Given the broad potential of the platform and our team’s deep expertise with challenging drug targets, we are excited to deploy Basecamp Bio to both advance our own pipeline and enable early-stage drug discovery partnerships to extend the reach of our leading-edge science,” Melita Sun Jung, Chief Business Officer, ShouTi About ShouTi ShouTi is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company’s cutting-edge technology platform leverages structure-based drug discovery and computational chemistry expertise and enables ShouTi to develop oral small molecule therapeutics for the treatment of various diseases, including those in the metabolic, cardiovascular, and pulmonary therapeutic areas. By leveraging ShouTi’s world-class GPCR know-how, the company aims to design differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies targeting this family of receptors.

Read More

CELL AND GENE THERAPY

Fulgent Genetics Announces Strategic Investment in Spatial Genomics

Fulgent Genetics, Inc. | February 24, 2022

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Capital and other investors. Fulgent is also entering into commercial arrangements with Spatial to integrate Spatial Genomics’ seqFISH technology into Fulgent’s comprehensive genomic testing platform. Spatial Genomics has developed a spatial single-cell multiomics analysis platform based on the seqFISH technology originally developed in the laboratory of Professor Long Cai at the California Institute of Technology. seqFISH is a revolutionary technology designed to enable highly multiplexed and multiomic analyses of cells directly in the tissue microenvironments where they function, allowing researchers to identify novel cell types and cellular interactions, map genomic organization and nuclear architecture, and analyze cell trajectories far more efficiently than existing technologies. Under this arrangement, Fulgent expects to add Spatial Genomics’ multiomics analysis platform to the suite of lab services already available to its pharmaceutical and clinical research customer base. “We believe this strategic investment and commercial arrangement is an exciting opportunity for Fulgent as we will add Spatial Genomics’ leading seqFISH technology and multiomics analysis platform to our suite of genomic testing solutions. Spatial’s seqFISH technology is a highly promising platform that will enable clinicians to efficiently perform highly multiplexed single-cell analysis of RNA, DNA and proteins beyond the capabilities of other types of spatial analyses. We look forward to working with Spatial to commercialize this technology for broader reach and application.” Dr. Harry Gao, Chief Scientific Officer at Fulgent “We are excited to secure this Series A funding, which will support and accelerate our continued growth as a company, and the ongoing commercialization of our seqFISH technology platform,” said Kirsten Frieda, CEO and cofounder of Spatial Genomics. “seqFISH enables a highly multiplexed, quantitative, and multiomic analysis of cells and tissues that we believe will be essential to the next era of biological discovery, the continued evolution of precision medicine, drug and biomarker discovery, and the improvement of clinical diagnostics.” Spatial Genomics will use the funds from its Series A financing round to accelerate the commercialization of their seqFISH technology platform, grow their seqFISH laboratory services group, and aggressively expand their workforce, including in R&D, engineering, manufacturing, sales, marketing, customer support, and commercial operations. About Fulgent Genetics Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service, and automated lab services. About Spatial Genomics Spatial Genomics is a biology and life science technology company dedicated to empowering discovery. Spatial Genomics’ integrated technology platform consists of instrumentation, reagents, and software and is being developed with a vision of providing the highest possible multiplexity of multi-omic biological analysis capabilities. Our highly multiplexed spatial analysis technology will advance fundamental biology, precision medicine, drug and biomarker discovery, and lead to the improvement of clinical diagnostics.

Read More

CELL AND GENE THERAPY

Tevard Biosciences and Zogenix Collaborates to Identify and Develop Novel tRNA-based Gene Therapies for Dravet Syndrome and other Genetic Epilepsies

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platforms focused with respect to mRNA Stabilization and Nonsense Codon Suppression to find and advance novel drug candidates for the treatment of Dravet condition and other genetic epilepsies. Zogenix will additionally build up the up-and-comers through cutting edge preclinical examinations and clinical turn of events, and be responsible for overall commercialization.

Read More